Semaglutide Approved to Slash Heart Attack and Stroke Risks
More than one million individuals living with heart disease will soon receive a groundbreaking weight loss injection designed to prevent devastating heart attacks and strokes. The National Institute for Health and Care Excellence (NICE), the NHS’s spending watchdog, has greenlit the use of semaglutide for overweight and obese patients with specific cardiovascular conditions, aiming to dramatically reduce their risk of major cardiac events.
Known commercially as Wegovy, this weekly injection is a GLP-1 receptor agonist—a class of drugs that promotes weight loss by slowing digestion and enhancing satiety. Beyond aiding weight loss, clinical trials reveal that semaglutide exerts a direct protective effect on the heart and blood vessels, making it a dual-action therapy for cardiovascular health.
Who Qualifies for the Treatment?
NICE’s new guidance recommends semaglutide for patients with a body mass index (BMI) of 27 or higher, in conjunction with existing medications like statins, plus a reduced-calorie diet and increased physical activity. Experts estimate that approximately 1.2 million people across England could benefit from this intervention.
Rapid NHS Rollout and Proven Clinical Benefits
Semaglutide is already available on the NHS for obesity treatment and marketed as Ozempic for type 2 diabetes management. New evidence from a large-scale clinical trial involving 17,604 participants demonstrated a remarkable 20% reduction in the risk of heart attacks, strokes, or cardiovascular death among those treated with semaglutide.
Remarkably, these cardiovascular benefits appeared even before significant weight loss occurred, underscoring the drug’s direct positive impact on heart and vascular health.
NICE has declared the treatment cost-effective for NHS use and confirmed that semaglutide injections will be available to eligible patients within months.
Expert Voices Highlight Life-Saving Potential
Helen Knight, Director of Medicines Evaluation at NICE, emphasized the profound anxieties faced by heart attack and stroke survivors. “The clinical trial data is compelling. Patients taking semaglutide alongside their standard heart medications were significantly less likely to suffer another heart attack or stroke,” she stated.
Helen Williams, National Clinical Director for Cardiovascular Disease Prevention at NHS England, described the treatment as potentially “life-changing.” She stressed that, combined with healthy lifestyle changes, semaglutide could prevent thousands of future cardiovascular events, offering countless patients the prospect of a longer, healthier life.
